About Nkarta Nkarta Therapeutics was founded on the proprietary ... Deerfield Management, LSP, Logos Capital, NEA, Novo Holdings A/S, RA Capital Management, Samsara BioCapital and SR One.

Nkarta Therapeutics’ off-the-shelf natural killer cell therapy appears to be most effective against blood cancer when used with a specific lymphodepletion regimen. But that’s not what most ...

About Nkarta Nkarta Therapeutics was founded on the proprietary ... Deerfield Management, LSP, Logos Capital, NEA, Novo Holdings A/S, RA Capital Management, Samsara BioCapital and SR One.

In addition, Nkarta’s strategy is to use allogeneic CAR-NK cells as their therapeutics candidates. In other words, the company is aiming to manufacture large amounts of NK cells from healthy ...

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. This latest agreement follows a major deal with ...

Under the new deal, financials of which were not disclosed, gene-editing specialist CRISPR Therapeutics and NK cell therapy startup Nkarta will work together to seek out CRISPR/Cas9 gene-edited ...